Serum asprosin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome: A retrospective case-control study
- PMID: 37058072
- PMCID: PMC10101240
- DOI: 10.1097/MD.0000000000033526
Serum asprosin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome: A retrospective case-control study
Abstract
Dysregulation of adipokines may play a role in the development of polycystic ovary syndrome (PCOS). This was a retrospective case-control study to investigate the relationship between asprosin and insulin resistance in patients with PCOS patients. The study enrolled 213 PCOS patients and 213 age-matched and body mass index-matched controls. The serum asprosin levels and the relationship between asprosin and PCOS with IR were compared between the 2 groups. In the current study, it was found that the serum asprosin level and hemostasis of model assessment-insulin resistance of PCOS were significantly higher than those of the control group, and asprosin was independently correlated with hemostasis of model assessment-insulin resistance and CRP (P < .05). Asprosin was found to be statistically significant in the analysis of receiver operating characteristics, and the specific result was 0.826 (0.724-0.879). This study emphasizes that increased levels of asprosin are independently associated with PCOS, and asprosin may be a new indicator for evaluating insulin resistance in PCOS patients.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures
Similar articles
-
Achilles tendon thickness and serum asprosin level significantly increases in patients with polycystic ovary syndrome.PeerJ. 2024 Aug 22;12:e17905. doi: 10.7717/peerj.17905. eCollection 2024. PeerJ. 2024. PMID: 39184386 Free PMC article.
-
Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome.Gynecol Endocrinol. 2019 Mar;35(3):220-223. doi: 10.1080/09513590.2018.1512967. Epub 2018 Oct 16. Gynecol Endocrinol. 2019. PMID: 30325247
-
Serum asprosin level in different subtypes of polycystic ovary syndrome: a cross-sectional study.Rev Assoc Med Bras (1992). 2021 Apr;67(4):590-596. doi: 10.1590/1806-9282.20201147. Rev Assoc Med Bras (1992). 2021. PMID: 34495066
-
Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis.Gynecol Endocrinol. 2023 Dec;39(1):2152790. doi: 10.1080/09513590.2022.2152790. Epub 2022 Dec 8. Gynecol Endocrinol. 2023. PMID: 36480935
-
Asprosin: its function as a novel endocrine factor in metabolic-related diseases.J Endocrinol Invest. 2024 Aug;47(8):1839-1850. doi: 10.1007/s40618-024-02360-z. Epub 2024 Apr 3. J Endocrinol Invest. 2024. PMID: 38568373 Review.
Cited by
-
Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome.Front Endocrinol (Lausanne). 2025 May 19;16:1602622. doi: 10.3389/fendo.2025.1602622. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40458174 Free PMC article.
-
The association of plasma asprosin with anthropometric and metabolic parameters in Korean children and adolescents.Front Endocrinol (Lausanne). 2024 Oct 3;15:1452277. doi: 10.3389/fendo.2024.1452277. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39421535 Free PMC article.
-
Pathophysiological insights into asprosin: an emerging adipokine in reproductive health.Rev Endocr Metab Disord. 2025 Jun 9. doi: 10.1007/s11154-025-09975-4. Online ahead of print. Rev Endocr Metab Disord. 2025. PMID: 40488997 Review.
-
Achilles tendon thickness and serum asprosin level significantly increases in patients with polycystic ovary syndrome.PeerJ. 2024 Aug 22;12:e17905. doi: 10.7717/peerj.17905. eCollection 2024. PeerJ. 2024. PMID: 39184386 Free PMC article.
References
-
- Fauser BC, Tarlatzis BC, Rebar RW, et al. . Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.e25. - PubMed
-
- Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous